Business Context and Reporting Period
This Form 8-K Current Report was filed by Myriad Genetics, Inc. on December 10, 2024. The filing reports a corporate governance event involving the expansion of the Board of Directors and the appointment of a new director.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed relates to director compensation:
- Director Compensation Grant: A restricted stock unit award with an aggregate value of $350,000 was granted to the new director.
Material Changes
The primary material change reported is the increase in the size of the Board of Directors from eight to nine members. Mark S. Davis was appointed to fill the newly created vacancy, effective immediately, serving as a Class I Director with a term expiring at the 2027 Annual Meeting of Stockholders.
Outlook, Risks, and Management Commentary
The Board determined that Mr. Davis meets the independence requirements of the SEC and Nasdaq Stock Market Rules and qualifies as an "audit committee financial expert." He has been appointed to the Audit and Finance Committee effective immediately. There are no reported related party transactions or unusual items associated with this appointment. The filing incorporates by reference the Company's Non-Employee Director Compensation Policy and standard indemnification agreement.
Investor Verification Checklist
- Verify the vesting schedule of the $350,000 restricted stock unit grant (vests one year following the grant date).
- Review the "Director Compensation" section of the 2024 Proxy Statement for details on the compensation policy.
- Confirm the updated Board composition and committee assignments in subsequent filings.